Boston Scientific (BSX) is drawing fresh attention as investors weigh upbeat analyst commentary, steady demand across key device franchises, and expectations ahead of its February 4 earnings release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback